Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Clinical trial NCT01084252 · COMPLETED

Trial details

NCT number: NCT01084252
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Hematological Malignancy

Start date: 2010-05-11
Primary completion: 2018-12-21
Enrollment: 351

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.